Marex Group plc Purchases Shares of 6,426 Exact Sciences Corporation $EXAS

Marex Group plc acquired a new position in shares of Exact Sciences Corporation (NASDAQ:EXAS) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 6,426 shares of the medical research company’s stock, valued at approximately $341,000.

Several other hedge funds have also recently added to or reduced their stakes in EXAS. National Pension Service increased its position in shares of Exact Sciences by 75.1% in the 1st quarter. National Pension Service now owns 681 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 292 shares during the last quarter. Aberdeen Group plc raised its stake in Exact Sciences by 180.0% in the first quarter. Aberdeen Group plc now owns 172,565 shares of the medical research company’s stock valued at $7,470,000 after buying an additional 110,924 shares in the last quarter. Korea Investment CORP boosted its position in shares of Exact Sciences by 289.4% during the 1st quarter. Korea Investment CORP now owns 113,966 shares of the medical research company’s stock worth $4,934,000 after acquiring an additional 84,700 shares in the last quarter. Hsbc Holdings PLC boosted its position in shares of Exact Sciences by 1.8% during the 1st quarter. Hsbc Holdings PLC now owns 348,239 shares of the medical research company’s stock worth $15,067,000 after acquiring an additional 6,137 shares in the last quarter. Finally, Legacy Financial Advisors Inc. purchased a new position in shares of Exact Sciences in the 1st quarter valued at about $617,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analyst Ratings Changes

EXAS has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exact Sciences in a report on Wednesday, October 8th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $105.00 target price (up from $85.00) on shares of Exact Sciences in a research report on Thursday, November 20th. Wall Street Zen lowered shares of Exact Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Craig Hallum downgraded shares of Exact Sciences from a “buy” rating to a “hold” rating and set a $105.00 price objective for the company. in a research note on Friday, November 21st. Finally, Jefferies Financial Group lowered Exact Sciences from a “buy” rating to a “hold” rating and raised their price objective for the stock from $90.00 to $105.00 in a report on Monday, November 24th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, nineteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $85.00.

Insider Transactions at Exact Sciences

In related news, EVP Jacob A. Orville sold 5,000 shares of the stock in a transaction on Wednesday, November 19th. The stock was sold at an average price of $75.00, for a total transaction of $375,000.00. Following the completion of the sale, the executive vice president directly owned 23,237 shares of the company’s stock, valued at $1,742,775. This trade represents a 17.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Brian Baranick sold 2,858 shares of Exact Sciences stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $70.08, for a total transaction of $200,288.64. Following the completion of the transaction, the executive vice president owned 22,368 shares in the company, valued at approximately $1,567,549.44. This trade represents a 11.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 9,858 shares of company stock worth $695,289 over the last 90 days. 1.20% of the stock is currently owned by insiders.

Exact Sciences Price Performance

Shares of NASDAQ:EXAS opened at $101.74 on Tuesday. Exact Sciences Corporation has a one year low of $38.81 and a one year high of $101.95. The stock has a market capitalization of $19.28 billion, a price-to-earnings ratio of -19.12, a PEG ratio of 12.52 and a beta of 1.41. The company has a 50-day simple moving average of $77.91 and a 200-day simple moving average of $60.59. The company has a debt-to-equity ratio of 0.93, a quick ratio of 2.44 and a current ratio of 2.72.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.11. The firm had revenue of $850.74 million for the quarter, compared to analyst estimates of $810.42 million. Exact Sciences had a positive return on equity of 1.67% and a negative net margin of 32.01%.The business’s revenue was up 20.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.21) earnings per share. On average, analysts predict that Exact Sciences Corporation will post -0.58 EPS for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.